Myovant Sciences, Inc.
Myovant Sciences is focused on women’s health because when she moves forward, we all move forward. Relugolix combination therapy, an oral, once-daily GnRH receptor antagonist plus low-dose estradiol and norethindrone acetate, is in clinical development for uterine fibroids with recent completion of two replicate Phase 3 studies (LIBERTY 1 and LIBERTY 2). Relugolix combination therapy is also in clinical development for endometriosis-associated pain with two ongoing Phase 3 studies (SPIRIT 1 and SPIRIT 2). MVT-602, an oligopeptide kisspeptin-1 receptor agonist, is in clinical development for female infertility with recent completion of a Phase 2a study.